lapatinib has been researched along with Aneuploid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazrgar, M; Golkar-Narenji, A; Gourabi, H; Maleki, P; Tahmaseb, M | 1 |
| Arbushites, M; Di Leo, A; Downey, L; Guzman, R; Koehler, M; Livingston, RB; Press, MF; Santiago, A; Villalobos, I; Williams, L | 1 |
2 other study(ies) available for lapatinib and Aneuploid
| Article | Year |
|---|---|
Lapatinib Decreases the Preimplantation Aneuploidy Rate of in vitro Fertilized Mouse Embryos without Affecting Completion of Preimplantation Development.
Topics: Aneuploidy; Animals; Blastocyst; Embryonic Development; Fertilization in Vitro; Lapatinib; Male; Mice | 2020 |
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quinazolines; Treatment Outcome | 2010 |